CHICAGO – Results from the phase III POLO trial presented at the 2019 American Society of Clinical Oncology's (ASCO's) 2019 annual meeting on Sunday showed that treatment with Lynparza (olaparib, Astrazeneca plc/Merck & Co Inc.) after platinum chemotherapy nearly doubled the progression-free interval (progression-free survival, PFS) in a group of 154 metastatic pancreatic cancer patients with germline BRCA mutations, from 3.8 to 7.4 months.